Arbutus Biopharma Corp Deferred Costs, Current
Arbutus Biopharma Corp (ABUS) had Deferred Costs, Current of $57.00 thousand as of 2014-06-30, per its 10-Q filed 2014-08-14.
Discontinued › Balance Sheet › Assets › Assets, Current › Deferred Costs, Current
us-gaap:DeferredCostsCurrent · last filed 2014-11-07
- 2014-06-30: Deferred Costs, Current $57.00K.
- 2014-03-31: Deferred Costs, Current $111.00K.
- 2013-12-31: Deferred Costs, Current $173.00K.
| Period end | Deferred Costs, Current |
|---|---|
| 2014-06-30 | $57.00K 10-Q · filed 2014-08-14 |
| 2014-03-31 | $111.00K 10-Q · filed 2014-05-14 |
| 2013-12-31 | $173.00K 10-Q · filed 2014-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |